Tn Emis App

0 views

Skip to first unread message

Brinda

unread,

Aug 3, 2024, 5:33:32 PM8/3/24

to guttblunicspir

From what I understand this is a timestamp issue, but I have triple checked my emissions inputs netcdfs for 2019244 (attached) and they have the correct start time of 2019244:000000 and I have tested running straight from the second day and the GR_EMIS_001 is read in fine and runs for 2019244.

The CMAQ run script that EPA distributes is set up for multiple executions of the model, with each run being 24 hours. You have set NSTEPS to 1440000, or 144 hours, equal to 6 days. It is possible to do a single execution for 6 days (or far longer), but you need to have all your meteorology, emissions, IC/BCs, etc., available in the files specified by the run script. Here your gridded emissions file for September 1 contains only 24 time steps, and CMAQ does not know to look for the next file.

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

By leveraging market-leading point-of-care systems used and trusted in over 10,000 healthcare organisations across the UK, Proxemis will integrate research delivery into day-to-day care to address long-term conditions and health inequalities.

By focusing particularly on clinical trials that are suited to be conducted in primary care settings, Proxemis aims to make it easier for both patients and clinicians to participate in research, help find better treatments for long-term conditions and deliver research that is truly representative of the UK population.

Proxemis will be able to help design a study specifically to target relevant populations, particularly around a chronic condition, recruit patients for the study and enable a successful clinical trial.

The business will have a board consisting of three directors from EMIS: John McCormack, Alex Eavis and Lucy Mackillop and three from the University of Oxford: Professor Richard Hobbs, Bernard Taylor and Linda Naughton.